Results from a trial comparing three treatments for serious eye disease have shown that Regeneron and Bayer's Eylea is the most effective. The trial was sponsored by the US government-funded ...

The three-way study examined the safety and effectiveness of Novartis' Lucentis and Regeneron/Bayer's Eylea, both licensed to treat diabetic macular oedema (DME) and Roche/Genentech's Avastin ...

and safety as the main driver for physician use of branded Eylea vs. lower-cost (rival) therapies like compounded Avastin — making us believe that it may be challenging to prove whether ...

The trial, designed to compare the efficacy, safety, and immunogenicity of AVT06 with Eylea, reached the main goal, according to its topline data from January 2024. The duo said the FDA process to ...